Client Profile
The Challenge: Licensing Misalignment in a Regulated Growth Phase
This UK-based, LSE-listed pharmaceutical company operated Health Cloud (Life Sciences) across four European markets, with approximately 1,400 employees engaged in clinical, regulatory, and commercial operations. The company was approaching MHRA Phase 2 approval for a significant drug candidate—a milestone that would likely expand headcount and regulatory obligations, making forward-looking software economics critical.
When Redress was engaged six months before renewal, the licensing estate revealed multiple structural inefficiencies:
- Annual spend had increased 28% over two years, from £640K to £820K
- Agentforce for Sales added mid-contract at list price: £125/user/month for 95 sales users (£142,500/year)
- Health Cloud Life Sciences deployed uniformly at £175/user/month across all 180 users, despite diverse roles
- 40% of users were medical science liaisons (MSLs) with significantly lower feature requirements
- Marketing Cloud provisioned for 500K contact capacity but sending to only 140K contacts
- Einstein Activity Capture bundled but not actively deployed across the sales organization
- No growth clause to protect pricing in the event Phase 2 approval expanded the workforce
The company faced a contractual renewal with less than six months' notice. Without renegotiation, the assumption was that all licenses would roll forward at incumbent pricing, with no adjustment for regulatory phase transitions or headcount expansion.
The Approach: Role-Based Licensing and Commercial Protection
Redress began with a detailed user role audit, mapping every Health Cloud user by job function: sales representatives, MSLs, medical directors, regulatory specialists, and support staff. This segmentation revealed that while all users required Health Cloud access, the feature intensity differed significantly.
1. Health Cloud Tier Optimization
Medical science liaisons represent a specialized category of healthcare professional who educate physicians about the company's products but engage less frequently with customer relationship data than sales representatives. Salesforce offers a lower-cost "Life Sciences Partner Community" license at £35/user/month, designed specifically for this user type. Redress identified 72 users—40% of the total Health Cloud estate—as legitimate candidates for Partner Community downgrade.
This restructuring would move the company from a uniform £175/user/month model to a segmented cost structure: premium Enterprise Cloud for sales and regulatory roles (£175/user), mid-tier Professional licenses for clinical coordinators (£95/user), and Partner Community for MSLs (£35/user). The projected saving on this segment alone: £102,000 annually.
2. Agentforce Repricing Challenge
Agentforce for Sales had been added at full list price (£125/user/month) with no effort to benchmark against existing Einstein functionality. Redress conducted a detailed comparison of Agentforce capabilities against existing Einstein Einstein Sales Cloud features available under the standard Health Cloud license. We found that 85% of the Agentforce use case (lead scoring, opportunity insights, activity capture) was already included in Einstein Sales Cloud, making the incremental Agentforce value proposition marginal for this organization.
We presented this analysis to Salesforce with a formal repricing request, proposing £80/user/month as a more appropriate rate given the overlapping Einstein functionality. This constituted a 36% discount from list price and was justified by actual feature utilization.
3. Marketing Cloud Right-Sizing
The organization was paying for 500K contact capacity in Marketing Cloud but sending email campaigns to approximately 140K contacts (physicians, patient organizations, regulatory bodies). This represented a 3.6x over-provisioning ratio. By moving to the 250K contact tier—still providing 79% capacity headroom for growth—the company would reduce Marketing Cloud spend while maintaining operational flexibility.
4. Growth Clause for Regulatory Certainty
The critical strategic element was addressing the Phase 2 approval timeline. Post-approval headcount expansion could reach 40% within 24 months. Rather than locking into fixed pricing that would apply legacy rates to expanded headcount, Redress negotiated a "growth protection clause" allowing up to 40% headcount expansion at current per-user rates for the contract period. This protected the company from "penalty pricing" on growth-driven scaling.
The Outcome: 28% Reduction and Regulatory Headroom
Salesforce agreed to a restructured contract reducing annual spend from £820,000 to £594,000—a £226,000 annual saving (28% reduction). The restructuring addressed all four licensing inefficiencies while adding strategic growth protection.
| Component | Previous | Revised | Annual Saving |
|---|---|---|---|
| Health Cloud Enterprise (108 users) | £189K | £189K | — |
| Health Cloud Professional (32 users) | £56K | £30K | £26K |
| Health Cloud Partner Community (72 users @ £35) | £126K (at Enterprise rate) | £30K | £96K |
| Agentforce for Sales (95 users) | £142.5K (@ £125/user) | £91.2K (@ £80/user) | £51.3K |
| Marketing Cloud (500K → 250K tier) | £164K | £98K | £66K |
| Einstein Activity Capture & Add-ons | £52K | £36K | £16K |
| Total | £820K | £594K | £226K (28%) |
Strategic Commercial Terms
- Role-segmented Health Cloud pricing: 72 users migrated to Partner Community tier, saving £96K annually
- Agentforce repriced to £80/user/month: Down from list price of £125, saving £51K annually
- Marketing Cloud right-sized: 500K contact tier → 250K tier, saving £66K annually
- Growth protection clause: Up to 40% headcount expansion at current per-unit rates through 2027
- Fixed term commitment: 2-year contract at locked pricing, protecting against regulatory uncertainty
- 3-year total benefit: £678,000 (£226K × 3 years)
Key Takeaways
User role analysis uncovers significant tier opportunity. This organization had applied uniform licensing across 180 users without questioning whether every user required the same feature set. Medical science liaisons—a distinct professional category—can operate effectively on lower-tier licenses designed specifically for their role. Role-based licensing segmentation can often yield 15-25% savings without operational impact.
New add-ons should be evaluated against existing bundled functionality. Agentforce for Sales overlaps significantly with Einstein functionality available under standard licenses. When a vendor proposes a new add-on mid-contract, conduct a detailed feature comparison against existing capabilities. Many organizations accept add-ons at list price without evaluating whether the functionality is already included elsewhere.
Email contact tiers can be right-sized based on sending behavior. Marketing Cloud pricing is often driven by "just in case" provisioning rather than actual engagement volume. Auditing 12 months of email sends can reveal systematic over-provisioning. This company was paying for 3.6x excess capacity—a common pattern in regulated industries where headcount forecasts drive purchasing more than utilization data.
Regulatory transitions create opportunities for commercial protection. The Phase 2 approval milestone was a critical business event. Rather than ignoring it in the renewal, Redress positioned it as a growth scenario: the company deserves pricing protection if approved status drives headcount expansion. This "growth clause" protects both parties: Salesforce gets visibility to future revenue, and the company avoids penalty pricing during expansion.
Non-binding list prices are starting points, not baselines. Agentforce appeared expensive at £125/user/month. However, feature-based comparison revealed that the incremental value was marginal given existing Einstein bundling. This allowed Redress to propose a 36% discount grounded in actual utilization, not arbitrary negotiation.
The company now operates a right-sized Salesforce estate aligned with user roles and actual marketing engagement volume. The £226K annual saving will fund advanced Einstein analytics and workflow automation initiatives that drive clinical decision-making and regulatory compliance—higher-value investments than maintaining excess licensing capacity.